Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 4/20 | 0.32 |
| ▸ | CDK8 | P49336 | 4/20 | 0.32 |
| ▸ | HASPIN | Q8TF76 | 4/20 | 0.32 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23317039 | 0.85 | NAMPT (0.40) | CCNCCDK8HASPINNAMPT | |
| SCHEMBL31059130 | 0.85 | NAMPT (0.40) | CCNCCDK8HASPINNAMPT | |
| SCHEMBL23305078 | 0.83 | TRPM8 (0.38) | — | |
| SCHEMBL23304715 | 0.82 | IRAK4 (0.32) | — | |
| SCHEMBL23305171 | 0.80 | — | — | |
| SCHEMBL30200940 | 0.79 | CCNC (0.30) | CCNCCDK8HASPIN | |
| SCHEMBL23304778 | 0.79 | CCNC (0.30) | CCNCCDK8HASPIN | |
| SCHEMBL23305305 | 0.77 | — | — | |
| SCHEMBL23304876 | 0.77 | HPGDS (0.32) | — | |
| SCHEMBL23305557 | 0.77 | ACACB (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230060003-A1 | SPIROCYCLIC O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. | 2023-02-23 | — | — | US | disclosed |
| WO-2021086966-A1 | SPIROCYCLIC O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230060003-A1 | SPIROCYCLIC O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | MAN2A1, MAN2B2, ST6GAL1 | CCNC 1341/4885CDK8 3758/4885HASPIN 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.